Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to 97.6%

Gross margin was 97.6% in Q3 FY2026, down 0.6 pp from a year earlier. On a trailing-twelve-month basis it was 97.8%, down 0.6 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
97.6%+0.0 pp QoQ
Last fiscal yearDec 2025
98.2%-0.4 pp YoY
LTMSep 2026
97.8%-0.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.6 pp——
1 year-0.4 pp——
3 years-0.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
98.2%
Year-over-year change
-0.4pp

Gross Margin vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's LTM Sep 2026 gross margin of 97.8% is the highest of the 7 companies compared; the peer median is 90.3%.
  • Its year-over-year change of -0.6 pp is the 3rd highest of 6, against a peer median of -1.0 pp.
  • Over three fiscal years its change of -0.3 pp compares with a peer median of +3.0 pp.
NBIX Competitors Peer median
Gross Margin for NBIX and competitors
Company Period LTM level YoY 3-year change
NBIXNeurocrine Biosciences, Inc.LTM Sep 202697.8% -0.6 pp-0.3 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202695.0% ——
AXSMAxsome Therapeutics, Inc.LTM Jun 202693.2% +1.8 pp+3.0 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 202692.5% -1.0 pp+3.5 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202688.1% -0.5 pp+2.7 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202664.9% -27.0 pp-6.3 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202664.2% -21.2 pp+3.0 pp
BHVNBiohaven Ltd.FY2025— ——
GHRSGH Research PLCFY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding NBIX) 90.3%-1.0 pp+3.0 pp

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.13B1.49B1.89B2.36B2.86B
Cost of Revenue14.3M23.2M39.7M34M52.1M
Gross Profit1.12B1.47B1.85B2.32B2.81B
Gross Margin98.7%98.4%97.9%98.6%98.2%
Research & Development328.1M463.8M565M731.1M1.02B
Selling, General & Admin583.3M752.7M887.6M1.01B1.16B
Operating Expenses1.02B1.22B1.6B1.75B2.19B
Depreciation & Amortization10.9M15.6M21.3M27.1M30.1M
EBITDA138.1M236.6M416.1M639.7M666.6M
EBITDA Margin12.2%15.9%22.0%27.2%23.3%
Operating Income102.5M249M250.9M570.5M619.1M
Operating Margin9.0%16.7%13.3%24.2%21.6%
Interest Income011.2M091M90.3M
Interest Expense25.8M7.1M4.6M126.6M0
Other Income / Expenses(1.1M)(35.1M)81.2M(84.5M)86.3M
Income Before Tax101.4M213.9M332.1M486M705.4M
Pre-Tax Margin8.9%14.4%17.6%20.6%24.7%
Income Tax Expense11.8M59.4M82.4M144.7M226.8M
Net Income89.6M154.5M249.7M341.3M478.6M
Net Margin7.9%10.4%13.2%14.5%16.7%
EPS (Basic)0.951.612.563.404.81
EPS (Diluted)0.921.562.473.294.67
Weighted Avg Shares94.6M95.8M97.7M100.4M99.5M
Weighted Avg Shares (Diluted)97.9M98.9M101M103.7M102.5M

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.